With improvement in long-term survival after allogeneic stem cell transplantation, late complications with significant morbidity are of increasing importance. We retrospectively analysed 272 recipients of an allogeneic stem cell transplant for the development of osteonecrosis. The incidence among allograft recipients was 6.3% (17/272) for the whole patient population, and 11.8% (17/144) for long-term survivors. All patients were treated with high-dose prednisolone, 16 for severe acute or extensive chronic graft-versus-host disease (GVHD) and one patient for graft rejection. The mean age at time of diagnosis was 33 years (range 16-45) and the mean time from transplant to diagnosis of osteonecrosis was 13 months. Osteonecrosis was diagnosed by magnetic resonance (MR) imaging, which allows early detection of osteonecrosis and assessment of stage. At the time of diagnosis, eight patients had stage I, three patients stage II, three patients stage III and three patients stage IV osteonecrosis according to MR criteria. All but one patient had involvement of the femoral head. The median total dosage of prednisolone at the time of diagnosis was 189 mg/kg (single manifestation 150 mg/kg; multiple manifestations 313 mg/kg) with a total range of 13-555 mg/kg. Six patients were treated by conservative means, 77 patients underwent surgery (three core decompression, eight joint replacement). MR screening of patients receiving highdose steroids might help to detect osteonecrosis at an early stage and thus prevent progression by early intervention, for example, by core decompression. Keywords: avascular necrosis; allogeneic stem cell transplantation; magnetic resonance-steroids With improvement in long-term survival after allogeneic bone marrow transplantation, late complications with significant morbidity are of increasing importance.
1
There are several causes of osteonecrosis such as trauma, benign and malignant hematologic diseases, radiation, alcoholism, Gaucher's disease, collagen disease and decompression disease. [2] [3] [4] [5] [6] [7] [8] [9] Treatment with corticosteroids is another risk factor in the pathogenesis of osteonecrosis as first mentioned in 1950. 10 Therefore, avascular necrosis is a well-described complication after renal and cardiac transplantation, especially in patients receiving high-dose steroids for graft rejection. [10] [11] [12] [13] [14] [15] [16] [17] In 1987, Atkinson et al 18 first described a 10% incidence of osteonecrosis after allogeneic bone marrow transplantation from HLA-identical sibling donors. Since then, few studies have addressed this late complication. [19] [20] [21] [22] [23] We retrospectively analyzed 17 out of 272 patients after allogeneic stem cell transplantation who developed an avascular necrosis of the bone diagnosed by clinical symptoms and confirmed by MR imaging.
Patients and methods

Patients
Seventeen (eight female, nine male) out of 272 patients developed avascular necrosis after allogeneic stem cell transplantation (nine patients with CML, three AML, three ALL, two SAA). Eleven patients had undergone allogeneic transplantation from a matched sibling donor and six patients from a matched unrelated donor between 1987 and 1996 (see Table 1 ).
Conditioning regimens
Eight patients received TBI (12 Gy) and cyclophosphamide 60 mg/kg once daily for 2 days (total dose 120 mg/kg), with two patients receiving an additional dose of VP-16 (40 mg/kg). Five patients received busulfan 4 mg/kg p.o. in four divided doses daily for 4 days (total dose 16 mg/kg) in addition to intravenous cyclophosphamide (120 mg/kg). One patient was treated with cyclophosphamide (120 mg/kg) and ALG (Merieux, Leimen, Germany), and one patient with cyclophosphamide (4 × 50 mg/kg).
Supportive care
Patients were admitted to the hematologic intensive care unit and nursed in laminar air flow units until discharge. Max. pred. = maximal prednisolone dose. Supportive infusion therapy (parenteral feeding, vitamins) was administered through a tunneled Hickman catheter. Patients received prophylactic antibiotics, antifungal and antiviral drugs as well as passive immunoglobulin prophylaxis (0.25 mg/kg every 3 weeks).
GVHD prophylaxis and therapy
All patients received cyclosporin from day −1 until at least day +100 or longer, eight patients additionally received a short course of methotrexate (15 mg/m 2 day 1, 10 mg/m 2 days 3 and 6). Acute graft-versus-host disease grade II or more was treated with 2 mg/kg/day prednisolone. In nonresponding patients, the dose of prednisolone was increased to 5 mg/kg/day. If necessary, a further dose escalation was performed to 10 and finally 20 or more mg/kg/day. Tapering of the steroid dosage was initiated when clinical signs and symptoms of acute GVHD improved.
Diagnosis and staging of osteonecrosis
Symptomatic patients (pain, stiffness etc) were diagnosed by conventional radiography and MR imaging. Osteonecrosis was classified according to MR criteria: stage I: non-homogenous loss in signal intensity in T1; II: wedgeshaped crescent sign; III: crescent sign sequestra/cortical collapse; IV: degenerative changes with narrowed joint space.
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Results
Seventeen out of 272 recipients of an allogeneic marrow transplant developed avascular necrosis as a long-term complication. The incidence was 6.3% among all patients and 11.8% (17/144) for long-term survivors. All 17 patients received prednisolone treatment post-transplant; 16 patients for treatment of acute severe GVHD (one patient grade I, 13 patients grade II, one patient grade III and one patient grade IV) and one patient for graft rejection. The average maximum prednisolone dose was 13 mg/kg/day with a range of 2-27 mg/kg/day. At the time of diagnosis of osteonecrosis the average age was 33 years (range 16-45 years) and the mean time from transplant to manifestation of osteonecrosis was 13 months (Table 2 ). On the appearance of clinical symptoms such as pain and stiffness, only 8/17 patients were diagnosed as having stage I osteonecrosis according to MR criteria (Figure 1 ), all other patients had already progressed to more advanced stages: three patients to stage II, three to stage III and three to stage III/IV. All but one patient developed osteonecrosis of the femoral head, 10 patients had unilateral and four patients bilateral manifestations. Three patients showed involvement of three joints, two with bilateral disease of the femoral head and one of the humerus. A further patient had involvement of both knees and one humerus. The median total dose of prednisolone at the time of diagnosis was 189 mg/kg (single manifestation 150 mg/kg, multiple manifestations 313 mg/kg) with a total range of 13-555 mg/kg. All patients were initially treated conservatively with reduced weight-bearing and analgesia. Core decompression was performed in three patients (stage I) and six patients required joint replacement. All but one (patient No. 16) patient diagnosed in stage I and treated conservatively progressed to stages III and IV after a median follow-up of 2 years ( Figure 2 ). Two patients who had core decompression performed in stage I progressed to stages III and IV, whereas one patient undergoing core decompression remained in stage I/II during an 18 months follow-up period.
Discussion
Avascular necrosis of the bone has been recognised as a complication of systemic corticosteroid therapy since 1950. 10 In 1987, Atkinson et al 18 reported osteonecrosis for the first time following allogeneic bone marrow transplantation. Although few reports have addressed this complication of allogeneic stem cell transplantation, [19] [20] [21] [22] [23] improvement in the detection of this late complication with its attendant morbidity is of increasing importance.
Early diagnosis of avascular necrosis appears essential to prevent progression. MR imaging allows the detection of osteonecrosis while conventional radiographs still show no signs of osteonecrosis (Figure 1) . Therefore, MR imaging is clearly the technique of choice for early diagnosis and follow-up evaluations. 24, [28] [29] [30] [31] Breitenseher et al 32 showed that MR imaging achieved the best agreement with the definite diagnosis in distinguishing early avascular necrosis from bone marrow edema compared to radiography, CT and scintigraphy. Glickstein et al 33 reported a specificity of 98% and a sensitivity of 97% in differentiating avascular necrosis from normal hips. In contrast to Atkinson et al, 18 we were able to diagnose osteonecrosis in eight patients (44%) at stage I with MR criteria while radiographs remained normal. Sixty-five percent of our patients were diagnosed prior to developing advanced disease (III-IV) compared to 50% reported by Enright et al. 19 In our study, all patients had received prednisolone as treatment of GVHD or graft rejection. The mean maximal dose of prednisolone was 3 mg/kg/day (range 2-27). The median total dose of prednisolone was 189 mg/kg with a range of 13-555 mg/kg. Socie et al 22 reported a range of the cumulative steroid dose of 60-840 mg/kg in their patients with osteonecrosis, but others observed osteonecrosis in a patient who had received a total dose of only 14 mg/kg. 18 The mean age at diagnosis was 33 years (range 16-44) with only two patients younger than 20 years. These data are comparable to other series which demonstrated increasing age as an independent risk factor. 19, 22 We observed an incidence of osteonecrosis after allogeneic stem cell transplantation of 11.8% among long-term survivors, comparable to previous reports. 18, 19, 22 No male predominance was observed in our study and only one report shows male gender as an independent risk factor. 22 Even if 10 out of 17 patients (59%) showed multifocal manifestations it is noteworthy that the femoral head was involved in all but one of our patients. In contrast to Socie et al, 22 there was a significant difference in median total dosage of prednisolone at the time of diagnosis between single and multiple manifestations (single manifestation, median prednisolone dose 150 mg/kg, mean prednisolone dose 132 mg/kg; multiple manifestation, median prednisolone dose 313 mg/kg, mean prednisolone dose 333 mg/kg). However, there was no significant correlation between total dose and stage of osteonecrosis at the time of diagnosis (mean total prednisolone dose stage I and II, 240 mg/kg; mean total prednisolone dose stage III and IV, 212 mg/kg). Enright et al 19 reported similar results. The mean time from transplant to diagnosis was 13 months (range day +95 to day +865), similar to all other studies. [18] [19] [20] 22 Thus, osteonecrosis seems to occur earlier after bone marrow transplantation than in patients treated with steroids for systemic lupus erythematosus (3.5-5.5 years) 2 or after cardiac transplantation (2.5 years). [14] [15] [16] [17] All our patients were initially treated conservatively. At follow-up, three patients underwent core decompression and eight required joint replacement. Unfortunately, all patients diagnosed at an early stage and treated conservatively experienced progression of osteonecrosis after a median time of 2 years. Two further patients undergoing core decompression at a more advanced stage showed progression soon afterwards. Only one patient presented with stable disease (stage I/II) continuing 18 months after core decompression. Controversial results are reported following core decompression, even in the early stages of avascular necrosis, but many surgeons feel the technique may be effective if the diagnosis is established early. 24, 33, 34 There are reports of complete resolution or stable disease in 40% of patients when treated in stages I and II, but also of progression of avascular necrosis in 60% of patients treated with core decompression. 25, 34, 35 The role of intertrochanteric osteotomy for the treatment of avascular necrosis stages II or III of the femoral head in patients after allogeneic stem cell transplantation is not yet known. In patients with stage III disease with total hip involvement or stage IV, total hip arthroplasty is the procedure of choice.
Further studies will hopefully show whether diagnosis of avascular necrosis by MR imaging and subsequent core decompression at an early stage is able to prevent disease progression.
